Literature DB >> 8080050

Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness.

M Hsiao1, J Low, E Dorn, D Ku, P Pattengale, J Yeargin, M Haas.   

Abstract

Leukemia cell infiltration and the induction of lethal hematopoietic disease in immune-deficient SCID mice transplanted with human T cell acute lymphoblastic T leukemia (T-ALL) cells occurred only when the cells possessed mutant p53 genes and lacked a wild-type allele or when T-ALL cells lacking p53 protein were infected with specific mutant p53 genes. A series of six mutant p53 genes were cloned from relapse T-ALL-derived cell lines and were constructed into defective retroviral expression vectors. Viruses encoding mutant p53 proteins were used to infect relapse T-ALL cells in a study designed to compare their pathogenic potency. The mutant p53 genes possessed a distinct hierarchy in vivo and in vitro: mutants inducing the greatest increase in proliferation of different T-ALL lines in vitro and colony formation in methylcellulose cultures also induced tissue invasiveness of infected T-ALL cells in vivo. Mutant p53 gene transfer to a cell line lacking p53 protein showed that the more potent p53 mutants possessed a distinctive dominant oncogenic activity in vitro and in vivo. The dominant oncogenic activity of these mutant p53 proteins was not dependent on the presence of and on complex formation with wild-type p53 protein. These "hot" p53 mutations thus represent bona fide gain-of-function mutations. Infection of p53-negative T-ALL cells with viruses encoding gain-of-function mutant p53 genes resulted in the acquisition of metastatic potential and tissue invasiveness. Taken together, our results suggest that specific mutant p53 genes play a role in the generation of lymphohematopoietic metastatic potential and tissue invasiveness as assayed in SCID mice, whereas the expression of wild-type p53 is capable of keeping this metastatic potential in check.

Entities:  

Mesh:

Year:  1994        PMID: 8080050      PMCID: PMC1890319     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  77 in total

1.  Genetic mechanisms of tumor suppression by the human p53 gene.

Authors:  P L Chen; Y M Chen; R Bookstein; W H Lee
Journal:  Science       Date:  1990-12-14       Impact factor: 47.728

2.  Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges.

Authors:  O Danos; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

3.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

4.  Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype.

Authors:  T Frebourg; M Sadelain; Y S Ng; J Kassel; S H Friend
Journal:  Cancer Res       Date:  1994-02-15       Impact factor: 12.701

5.  Wild type human p53 is antiproliferative in SV40-transformed hamster cells.

Authors:  W E Mercer; M Amin; G J Sauve; E Appella; S J Ullrich; J W Romano
Journal:  Oncogene       Date:  1990-07       Impact factor: 9.867

6.  Gain of function mutations in p53.

Authors:  D Dittmer; S Pati; G Zambetti; S Chu; A K Teresky; M Moore; C Finlay; A J Levine
Journal:  Nat Genet       Date:  1993-05       Impact factor: 38.330

7.  Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV).

Authors:  P K Pattengale; C R Taylor; P Twomey; S Hill; J Jonasson; T Beardsley; M Haas
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

8.  Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein.

Authors:  P R Yew; A J Berk
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

Review 9.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

10.  Be13, a human T-leukemia cell line highly sensitive to dexamethasone-induced cytolysis.

Authors:  U Galili; A Peleg; Y Milner; N Galili
Journal:  Cancer Res       Date:  1984-10       Impact factor: 12.701

View more
  34 in total

1.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  RGS-GAIP-interacting protein controls breast cancer progression.

Authors:  Ling Wang; Julie S Lau; Chitta Ranjan Patra; Ying Cao; Santanu Bhattacharya; Shamit Dutta; Debashis Nandy; Enfeng Wang; Chamila N Rupasinghe; Pawan Vohra; Mark R Spaller; Debabrata Mukhopadhyay
Journal:  Mol Cancer Res       Date:  2010-10-27       Impact factor: 5.852

3.  Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.

Authors:  K Will; G Warnecke; L Wiesmüller; W Deppert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

4.  Inhibition of stress-inducible kinase pathways by tumorigenic mutant p53.

Authors:  Yoichi Ohiro; Anny Usheva; Shinichiro Kobayashi; Shannon L Duffy; Regan Nantz; David Gius; Nobuo Horikoshi
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

5.  An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.

Authors:  A Gualberto; K Aldape; K Kozakiewicz; T D Tlsty
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

6.  Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.

Authors:  Gang Chen; Paritosh Ghosh; Thomas O'Farrell; Rachel Munk; Louis J Rezanka; Carl Y Sasaki; Dan L Longo
Journal:  J Biol Chem       Date:  2012-05-23       Impact factor: 5.157

7.  Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.

Authors:  W Hanel; N Marchenko; S Xu; S Xiaofeng Yu; W Weng; U Moll
Journal:  Cell Death Differ       Date:  2013-03-29       Impact factor: 15.828

8.  p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug.

Authors:  Shu-Ping Wang; Wen-Lung Wang; Yih-Leong Chang; Chen-Tu Wu; Yu-Chih Chao; Shih-Han Kao; Ang Yuan; Chung-Wu Lin; Shuenn-Chen Yang; Wing-Kai Chan; Ker-Chau Li; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Nat Cell Biol       Date:  2009-05-17       Impact factor: 28.824

9.  Mutant p53 mediates survival of breast cancer cells.

Authors:  L Y Lim; N Vidnovic; L W Ellisen; C-O Leong
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

10.  Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.

Authors:  Peixin Dong; Zhujie Xu; Nan Jia; Dajin Li; Youji Feng
Journal:  Mol Cancer       Date:  2009-11-16       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.